Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GALK1 | P51570 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2742307 | 0.86 | KDM4E (0.55) | KDM4ELMNAGAACYP1A2CYP3A4 | |
| SCHEMBL231004 | 0.78 | KMT2A (0.40) | KDM4ELMNAGAACYP1A2CYP3A4 | |
| SCHEMBL230478 | 0.74 | KMT2A (0.38) | KDM4ELMNAGAAMAPTMEN1 | |
| SCHEMBL15354357 | 0.71 | ELANE (0.43) | KDM4ELMNACYP3A4CYP2C9MAPT | |
| SCHEMBL231970 | 0.65 | CYP1A2 (0.43) | KDM4ELMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL230540 | 0.65 | KDM4E (0.51) | KDM4ELMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL229821 | 0.64 | CYP1A2 (0.44) | KDM4ELMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2742298 | 0.64 | ELANE (0.40) | KDM4ELMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2742313 | 0.62 | ELANE (0.52) | KDM4ELMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL232448 | 0.62 | TP53 (0.45) | KDM4ELMNACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359362-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-9359362-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-20140038988-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038988-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-8569314-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569314-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| EP-2385945-B1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER IP GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2385945-B1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER IP GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | US | disclosed |
| EP-2385945-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | Bayer Pharma Aktiengesellschaft (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-8041896-B2 | Virtualization platform with dedicated cache access | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2010078953-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010078953-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038988-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | KEAP1, NOX4, NOX5 | KDM4E 4248/4885LMNA 2053/4885GAA 1164/4885 |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | KEAP1, NOX4, NOX5 | KDM4E 4248/4885LMNA 2053/4885GAA 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.